-
公开(公告)号：US20140341926A1
公开(公告)日：2014-11-20
申请号：US14450342
申请日：2014-08-04
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： A61K39/39558 , A61K31/517 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/2863 , A61K2300/00
摘要： The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
摘要翻译： 本发明涉及一种治疗患有由失调的人表皮生长因子受体（HER / Human EGFR）驱动的癌症的患者的方法，其中根据平均每日剂量的连续方案施用不可逆的酪氨酸激酶抑制剂（TKI） 在10至50mg的范围内，mAB根据给药方案共同施用，范围从50-500mg / m2的平均每周iv剂量重复三次，每周两次或一次，两周一次，一次在两周内 三周或至少每月一次需要这种治疗的患者。
-
公开(公告)号：US20130289056A1
公开(公告)日：2013-10-31
申请号：US13817571
申请日：2011-08-24
IPC分类号： A61K31/517 , C12Q1/68 , A61K31/426 , G01N33/74
摘要： Disclosed are methods of treating a patient having cancer with an EGFR inhibitor requiring an active step of avoiding or modifying the co-administration of such drugs with P-gp modulators. This invention also relates to a medicament for treating a patient having cancer, comprising an EGFR inhibitor as the active product ingredient, customized for avoiding co-administration with P-gp inducers and/or inhibitors by an instruction added to the medicament or the package containing said medicament.
摘要翻译： 公开了用EGFR抑制剂治疗患有癌症的患者的方法，其需要用P-gp调节剂避免或改变这种药物的共同给药的主动步骤。 本发明还涉及用于治疗患有癌症的患者的药物，其包含EGFR抑制剂作为活性成分成分，其特征在于避免通过加入到药物中的指令与P-gp诱导剂和/或抑制剂的共同给药或包含 所述药物。
-
公开(公告)号：US20120294867A1
公开(公告)日：2012-11-22
申请号：US13471500
申请日：2012-05-15
IPC分类号： A61K39/395 , A61P35/04 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/517 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/2863 , A61K2300/00
摘要： The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
摘要翻译： 本发明涉及一种治疗患有由失调的人表皮生长因子受体（HER / Human EGFR）驱动的癌症的患者的方法，其中根据平均每日剂量的连续方案施用不可逆的酪氨酸激酶抑制剂（TKI） 在10至50mg的范围内，mAB根据给药方案共同施用，范围从50-500mg / m2的平均每周iv剂量重复三次，每周两次或一次，两周一次，一次在两周内 三周或至少每月一次需要这种治疗的患者。
-
4.发明授权公开(公告)号：US08828391B2
公开(公告)日：2014-09-09
申请号：US13471500
申请日：2012-05-15
CPC分类号： A61K39/39558 , A61K31/517 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/2863 , A61K2300/00
摘要： The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
摘要翻译： 本发明涉及一种治疗患有由失调的人表皮生长因子受体（HER / Human EGFR）驱动的癌症的患者的方法，其中根据平均每日剂量的连续方案施用不可逆的酪氨酸激酶抑制剂（TKI） 在10至50mg的范围内，mAB根据给药方案共同施用，范围从50-500mg / m2的平均每周iv剂量重复三次，每周两次或一次，两周一次，一次在两周内 三周或至少每月一次需要这种治疗的患者。
-
-
-
搜索结果
4 条记录 (耗时 0.018 秒)